📝 Nidan Laboratories and Healthcare Limited — results explained
Quarter ended March 2026 (Q4 FY26)
Nidan Laboratories and Healthcare Limited reported revenue of ₹12 crore for the quarter ended March 2026 (Q4 FY26), down 11.2% from ₹14 crore in the same quarter last year.
Net profit fell 92.0% year-on-year to ₹0 crore, from ₹1 crore. Earnings per share (EPS) came in at ₹0.05.
Operating profit stood at ₹2 crore — an operating margin (OPM) of 18.5%, compared with 17.6% in the year-ago quarter.
Full year and trailing twelve months
On a trailing-twelve-month (TTM) basis, revenue stands at ₹26 crore with a net profit of ₹2 crore.
Valuation snapshot
At the current price of ₹13.40, NIDAN has a market capitalisation of ₹19 crore and a trailing P/E of about 12.4.
Within the Healthcare industry, it is the 21st-largest of the 22 companies we track by market value.
Shareholding pattern
As of Mar 2026, promoters held 57.04%, public shareholders 42.96% of Nidan Laboratories and Healthcare Limited.